DocSafe Search · for Canadian pharma brands
Physicians are already asking AI for clinical answers. Pharma's regulated channel has no way to answer.
DocSafe Search is AI search for pharma HCP portals — plain-language questions, verbatim answers from the brand's own PAAB-approved documents, no AI-generated prose.
Following initiation of [Drug], renal function should be assessed at baseline and every four weeks for the first three months, then every three months thereafter in patients with eGFR < 60. Dose adjustment may be warranted if...
... see full Product Monograph for complete monitoring criteria and dose modifications.
Reviewed by and referenced against
- PAAB
- Canada Health Infoway
- American Medical Association
- Varn Health
- Canadian Medical Association
Act 1 · The problem
The shift is already here.
Physicians and the students becoming physicians are using AI to answer clinical questions — with or without a regulated option.
The behavior is not niche, not experimental, and not slowing down. The numbers below are from the last eighteen months. They describe a category that pharma's regulated channel is not yet serving.
of Canadian medical students use Google to study; 56% keep using it in clinical rotations.
Canada Health Infoway, 2025
US physicians now use AI tools in clinical practice — up 78% in a single year.
AMA, 2025
of physicians say AI-powered search results have directly influenced their clinical decisions.
Varn Health, 2025
What pharma lost while no one was looking.
Every clinical question an HCP asks outside the brand's domain is a question pharma can't see, can't audit, and can't stand behind.
There is no audit trail. There is no fair balance. There is no way to know what an HCP was told about a drug before they prescribed it — because the question went to a chatbot trained on the open web. The behavior is mainstream. The framework is missing. And every month that gap stays open, the brand microsite matters less and the regulator's blind spot gets wider.
Act 2 · The product
Meet DocSafe Search.
DocSafe Search is AI-native search for a single pharma brand's PAAB-approved document library — every answer is a verbatim passage from the real source PDF, delivered alongside the brand's fair balance, on the non-linear website standard PAAB already recognizes.
Pipeline
- 01 query
- ↓ vector search
- ↓ verbatim passage match
- 02 full PDF, opened to the page
No path in the pipeline writes. There is nothing to unlock.
How it works.
The system is architecturally incapable of generating medical content.
Most AI search tools write an answer, then try to cite a source. DocSafe Search does the opposite. Every query runs against a vector index built from the brand's approved PDFs. The AI's only job is to find the passage that matches — word for word — and return the page it sits on. If the match fails validation against the source, it is discarded.
Nothing is paraphrased. Nothing is summarized. There is no prompt, no guardrail, no instruction the system could follow to produce novel medical language, because there is no mechanism in the pipeline that writes. This is not a policy. It is the shape of the software.
A real question. A real PDF. A real highlight. No AI paragraphs in between.
The physician's words go in. The brand's approved document comes out — opened to the page, highlighted on the passage, with the fair balance where PAAB expects it.
- 01 · query echoed above the result
- 02 · PDF filename and PAAB eFile number
- 03 · yellow-highlighted verbatim passage
- 04 · page-number indicator
- 05 · fair balance visible · non-linear standard
- 06 · no AI-generated text, anywhere
Query
What's the recommended monitoring schedule for patients on [Drug] with renal impairment?
Product Monograph · page 14
Following initiation of [Drug], renal function should be assessed at baseline and every four weeks for the first three months, then every three months thereafter in patients with eGFR < 60 mL/min/1.73m². Dose adjustment may be warranted if creatinine rises by more than 30% from baseline; refer to Section 4.2 for titration guidance and Section 4.8 for the complete adverse reaction profile.
How this is different from what HCPs use now.
Every tool listed here will answer a clinical question. Only one of them is allowed to.
| Google AI Search | ChatGPT + PDFs | DocSafe Search | |
|---|---|---|---|
| Content source | ✕ Open web, unverified | ✕ Any uploaded file | ✓ Brand's PAAB-approved library only |
| Answer format | ✕ AI-generated prose | ✕ AI-generated prose, may hallucinate | ✓ Verbatim quote from the source PDF |
| Full source delivered | ✕ Snippets only | ✕ Summary only | ✓ Complete PDF, opened to the page |
| Fair balance | ✕ None | ✕ None | ✓ Displayed per PAAB non-linear standard |
| Audit trail | ✕ None | ✕ None | ✓ Permanent, per-query, attributable |
| Regulatory posture | · Out of scope | · Out of scope | ✓ PAAB feasibility confirmed · template path defined |
Every other AI search tool paraphrases. DocSafe Search doesn't — by design.
The others are tools an HCP might reach for in spite of the regulatory framework. This one is the framework.
See it running against a real PAAB-reviewed library.
Act 3 · The result
What a brand can now do.
The same AI behavior HCPs reach for elsewhere, living inside the regulated channel that was built to carry it.
01
Keep HCPs on the brand domain for clinical questions about the product.
The search experience is the one they already use — natural language in, real source out — except it runs against approved material, not the open web.
02
Answer regulator and internal reviewer questions before they are asked.
Every query is logged and attributable; every extraction run is immutable; fair balance renders on the non-linear website standard PAAB already recognizes.
03
Ship AI-enabled search on every brand microsite without re-litigating AI with PAAB.
Stage 1 is one template review; Stage 2 is an incremental APS submission per brand — the scalability is the point.
PAAB · Feb 20, 2026 · Mar 17, 2026
Why this is credible right now.
The regulator has already said the concept is feasible and written down how to get it approved.
On February 20, 2026, PAAB confirmed that DocSafe Search's concept is feasible. On March 17, 2026, PAAB issued written guidance defining a two-stage template review path — one template approval, unlimited brand deployments downstream. That is the difference between "novel AI application, regulator unsure" and "sanctioned pattern, template eFile number pending." No other AI search tool serving Canadian pharma HCPs can say the same.
See it running against a real PAAB-reviewed library.
Twenty minutes, one working session. You'll see DocSafe Search running against a live PAAB-reviewed document set and walk through the template submission Adpharm is preparing for PAAB — the same template every future brand deployment will reference.